Skip to main content
PMC home page
Journal of Medical Toxicology logoLink to Journal of Medical Toxicology
. 2010 Jun 8;6(4):408–412. doi: 10.1007/s13181-010-0093-7

Non-muscarinic Therapeutic Targets for Acute Organophosphorus Poisoning

Christopher Rosenbaum 1, Steven B Bird 1,✉
PMCID: PMC3550473  PMID: 20532844

Abstract

Organophosphorus (OP) pesticides are a broad class of acetylcholinesterase inhibitors that are responsible for tremendous morbidity and mortality worldwide, contributing to an estimated 300,000 deaths annually. Current pharmacotherapy for acute OP poisoning includes the use of atropine, an oxime, and benzodiazepines. However, even with such therapy, the mortality from these agents is as high as 40%. It is increasingly recognized that not all OPs are the same. Significant differences exist in their toxicity, lipophilicity, and response to oxime therapy. Other non-muscarinic effects of OP pesticides exist, such as acute and chronic neuromuscular junction failure and central respiratory failure. In part because most of the mortality from these chemicals takes place in the developing world, little National Institutes of Health (NIH) research has been directed towards these agents. However, the similar mechanism of action of OP pesticides and the military nerve agents, along with increasing concerns about chemical terrorism has lead to the formation of the NIH Countermeasures Against Chemical Threats (CounterACT) Program. As part of the CounterACT Program, the NIH has recently designated six OP pesticides as “threat agents”. This concept paper describes some of the knowledge gaps related to non-muscarinic effects of OP pesticides and highlights needed areas of further research. Leveraging the current NIH interest in these chemicals to medical necessities in the developing world offers the possibility of delivering new therapeutics where they are needed on a daily basis.

Keywords: Organophosphorus, Nicotinic, Muscarinic, Poisoning

Full Text

The Full Text of this article is available as a PDF (116.4 KB).

Acknowledgments

This work was supported, in part, by a grant from the National Institute of Environmental Health Science (R21ES14019) to SBB.

This manuscript responds, in part, to the NIH program announcement PA-10-019.

References

  • 1.Eyer F, Meischner V, Kiderlen D, et al. Human parathion poisoning. A toxicokinetic analysis. Toxicol Rev. 2003;22:143–163. doi: 10.2165/00139709-200322030-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Zilker T, Hibler A. Treatment of severe parathion poison: clinical aspects. In: Szinicz L, Eyer P, Klimmek R, editors. Role of oximes in the treatment of anticholinesterase agent poisoning. Heidelberg: Spektrum, Akademischer; 1996. pp. 9–17. [Google Scholar]
  • 3.Eddleston M, Eyer P, Worek F, et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet. 2005;366:1452–1459. doi: 10.1016/S0140-6736(05)67598-8. [DOI] [PubMed] [Google Scholar]
  • 4.Sidell FR. Clinical effects of organophosphorus cholinesterase inhibitors. J Appl Toxicol. 1994;14:111–113. doi: 10.1002/jat.2550140212. [DOI] [PubMed] [Google Scholar]
  • 5.Thiermann H, Szinicz L, Eyer P, et al. Correlation between red blood cell acetylcholinesterase activity and neuromuscular transmission in organophosphate poisoning. Chem Biol Interact. 2005;157–158:345–347. doi: 10.1016/j.cbi.2005.10.102. [DOI] [PubMed] [Google Scholar]
  • 6.Eddleston M, Dawson A, Karalliedde L, et al. Early management after self-poisoning with an organophosphorus or carbamate pesticide—a treatment protocol for junior doctors. Crit Care. 2004;8:R391–397. doi: 10.1186/cc2953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sivilotti ML, Bird SB, Lo JC, et al. Multiple centrally acting antidotes protect against severe organophosphate toxicity. Acad Emerg Med. 2006;13:359–364. doi: 10.1111/j.1553-2712.2006.tb00309.x. [DOI] [PubMed] [Google Scholar]
  • 8.Bird SB, Gaspari RJ, Dickson EW. Early death due to severe organophosphate poisoning is a centrally mediated process. Acad Emerg Med. 2003;10:295–298. doi: 10.1111/j.1553-2712.2003.tb01338.x. [DOI] [PubMed] [Google Scholar]
  • 9.Eddleston M, Singh S, Buckley N. Organophosphorus poisoning (acute) Clin Evid. 2005;9:1744–1755. [PubMed] [Google Scholar]
  • 10.Ballantyne B, Marrs TC. Overview of the biological and clinical aspects of organophosphates and carbamates. Clinical and experimental toxicology of organophosphate and carbamates. Oxford: Butterworth Heinemann; 1992. pp. 3–14. [Google Scholar]
  • 11.Eddleston M, Eyer P, Worek F, et al. Pralidoxime in acute organophosphorus insecticide poisoning—a randomised controlled trial. PLoS medicine. 2009;6:e1000104. doi: 10.1371/journal.pmed.1000104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med. 1987;316:761–763. doi: 10.1056/NEJM198703263161301. [DOI] [PubMed] [Google Scholar]
  • 13.Senanayake N, Johnson MK. Acute polyneuropathy after poisoning by a new organophosphate insecticide. The New England journal of medicine. 1982;306:155–157. doi: 10.1056/NEJM198201213060306. [DOI] [PubMed] [Google Scholar]
  • 14.Li Y, Yu X, Wang Z, et al. Gastric lavage in acute organophosphorus pesticide poisoning (GLAOP)—a randomised controlled trial of multiple vs. single gastric lavage in unselected acute organophosphorus pesticide poisoning. BMC emergency medicine. 2006;6:10. doi: 10.1186/1471-227X-6-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Avasthi G, Singh G. Serial neuro-electrophysiological studies in acute organophosphate poisoning—correlation with clinical findings, serum cholinesterase levels and atropine dosages. J Assoc Physicians India. 2000;48:794–799. [PubMed] [Google Scholar]
  • 16.Jayawardane P, Senanayake N, Dawson A. Electrophysiological correlates of intermediate syndrome following acute organophosphate poisoning. Clinical toxicology Philadelphia, Pa. 2009;47:193–205. doi: 10.1080/15563650902832608. [DOI] [PubMed] [Google Scholar]
  • 17.Singh G, Sidhu UP, Mahajan R, et al. Phrenic nerve conduction studies in acute organophosphate poisoning. Muscle & nerve. 2000;23:627–632. doi: 10.1002/(SICI)1097-4598(200004)23:4<627::AID-MUS23>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  • 18.Sedgwick EM, Senanayake N. Pathophysiology of the intermediate syndrome of organophosphorus poisoning. Journal of neurology, neurosurgery, and psychiatry. 1997;62:201–202. doi: 10.1136/jnnp.62.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Karalliedde L, Henry JA. Effects of organophosphates on skeletal muscle. Human & experimental toxicology. 1993;12:289–296. doi: 10.1177/096032719301200406. [DOI] [PubMed] [Google Scholar]
  • 20.De Bleecker J, Van den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Critical care medicine. 1993;21:1706–1711. doi: 10.1097/00003246-199311000-00020. [DOI] [PubMed] [Google Scholar]
  • 21.Benson B, Tolo D, McIntire M. Is intermediate syndrome in organophosphate poisoning the result of insufficient oxime therapy. J Toxicol Clin Toxicol. 1992;30:347–349. doi: 10.3109/15563659209021549. [DOI] [Google Scholar]
  • 22.John M, Oommen A, Zachariah A. Muscle injury in organophosphorous poisoning and its role in the development of intermediate syndrome. Neurotoxicology. 2003;24:43–53. doi: 10.1016/S0161-813X(02)00111-0. [DOI] [PubMed] [Google Scholar]
  • 23.Dandapani M, Zachariah A, Kavitha MR, et al. Oxidative damage in intermediate syndrome of acute organophosphorous poisoning. The Indian journal of medical research. 2003;117:253–259. [PubMed] [Google Scholar]
  • 24.Katz EJ, Cortes VI, Eldefrawi ME, et al. Chlorpyrifos, parathion, and their oxons bind to and desensitize a nicotinic acetylcholine receptor: relevance to their toxicities. Toxicology and applied pharmacology. 1997;146:227–236. doi: 10.1006/taap.1997.8201. [DOI] [PubMed] [Google Scholar]
  • 25.De Bleecker J, Vogelaers D, Ceuterick C, et al. Intermediate syndrome due to prolonged parathion poisoning. Acta neurologica Scandinavica. 1992;86:421–424. doi: 10.1111/j.1600-0404.1992.tb05110.x. [DOI] [PubMed] [Google Scholar]
  • 26.De Bleecker J, Lison D, Van Den Abeele K, et al. Acute and subacute organophosphate poisoning in the rat. Neurotoxicology. 1994;15:341–348. [PubMed] [Google Scholar]
  • 27.De Bleecker JL. The intermediate syndrome in organophosphate poisoning: an overview of experimental and clinical observations. J Toxicol Clin Toxicol. 1995;33:683–686. doi: 10.3109/15563659509010628. [DOI] [PubMed] [Google Scholar]
  • 28.Jayawardane P, Dawson AH, Weerasinghe V, et al. The spectrum of intermediate syndrome following acute organophosphate poisoning: a prospective cohort study from Sri Lanka. PLoS medicine. 2008;5:e147. doi: 10.1371/journal.pmed.0050147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Pond W, Houpt K. The pig as a model in biomedical research. London: Comstock; 1978. [Google Scholar]
  • 30.Larsen M, Rolin B. Use of the Gottingen minipig as a model of diabetes, with special focus on type 1 diabetes research. ILAR Journal. 2004;45:303–313. doi: 10.1093/ilar.45.3.303. [DOI] [PubMed] [Google Scholar]
  • 31.Skytte C, Makin A. Measurement of cardiovascular effects in minipigs using telemetry. J Pharmacol Toxicol. 2008;58:172. doi: 10.1016/j.vascn.2008.05.107. [DOI] [Google Scholar]
  • 32.Thiermann H, Eyer P, Worek F, et al. Effects of oximes on muscle force and acetylcholinesterase activity in isolated mouse hemidiaphragms exposed to paraoxon. Toxicology. 2005;214:190–197. doi: 10.1016/j.tox.2005.06.013. [DOI] [PubMed] [Google Scholar]
  • 33.Eddleston M, Mohamed F, Davies JO, et al. Respiratory failure in acute organophosphorus pesticide self-poisoning. QJM. 2006;99:513–522. doi: 10.1093/qjmed/hcl065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Phys Rev. 2000;80:717–766. doi: 10.1152/physrev.2000.80.2.717. [DOI] [PubMed] [Google Scholar]
  • 35.Sollner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature. 1993;362:318–324. doi: 10.1038/362318a0. [DOI] [PubMed] [Google Scholar]
  • 36.Schwartz JH. Principles of Neural Science 3 rd ed. Norwalk: Appleton and Lange; 1991. [Google Scholar]
  • 37.Lotti M. Clinical toxicology of anticholinesterase agents in humans. Handbook of Pesticide Toxicology. San Diego: Academic; 2001. pp. 1043–1085. [Google Scholar]
  • 38.Evron T, Geyer BC, Cherni I, et al. Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath. Faseb J. 2007;21:2961–2969. doi: 10.1096/fj.07-8112com. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Colombo A, Orsi F, Bonfanti P. Exposure to the organophosphorus pesticide chlorpyrifos inhibits acetylcholinesterase activity and affects muscular integrity in Xenopus laevis larvae. Chemosphere. 2005;61:1665–1671. doi: 10.1016/j.chemosphere.2005.04.005. [DOI] [PubMed] [Google Scholar]
  • 40.Wecker L, Mrak RE, Dettbarn WD. Evidence of necrosis in human intercostal muscle following inhalation of an organophosphate insecticide. Fundam Appl Toxicol. 1986;6:172–174. doi: 10.1016/0272-0590(86)90273-3. [DOI] [PubMed] [Google Scholar]
  • 41.Tuler SM, Bowen JM. Toxic effects of organophosphates on nerve cell growth and ultrastructure in culture. J Toxicol Environ Health. 1989;27:209–223. doi: 10.1080/15287398909531292. [DOI] [PubMed] [Google Scholar]
  • 42.Flynn CJ, Wecker L. choline levels in brain. A non-cholinergic component of organophosphate toxicity. Biochemical pharmacology. 1986;35:3115–3121. doi: 10.1016/0006-2952(86)90395-3. [DOI] [PubMed] [Google Scholar]
  • 43.Worek F, Mast U, Kiderlen D, et al. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta. 1999;288:73–90. doi: 10.1016/S0009-8981(99)00144-8. [DOI] [PubMed] [Google Scholar]
  • 44.Padmaja D, Mantha S. Monitoring of Neuromuscular Juntion. Ind J Anaesth. 2002;46:279–288. [Google Scholar]
  • 45.Sheridan RD, Smith AP, Turner SR, et al. Nicotinic antagonists in the treatment of nerve agent intoxication. J R Soc Med. 2005;98:114–115. doi: 10.1258/jrsm.98.3.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.White SM, Palfreman TM. Nicotinic antagonists and nerve gas poisoning. J R Soc Med. 2005;98:336. doi: 10.1258/jrsm.98.7.336-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Breningstall GN, Kurachek SC, Fugate JH, et al. Treatment of congenital endplate acetylcholinesterase deficiency by neuromuscular blockade. J Child Neurol. 1996;11:345–346. doi: 10.1177/088307389601100416. [DOI] [PubMed] [Google Scholar]
  • 48.Besser R, Vogt T, Gutmann L. Pancuronium improves the neuromuscular transmission defect of human organophosphate intoxication. Neurology. 1990;40:1275–1277. doi: 10.1212/wnl.40.8.1275. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Toxicology are provided here courtesy of Springer

RESOURCES